24 May 2013
Keywords: bayhill, doses, ph, ii, ms, trial, raises
Article | 17 April 2006
California, USA-based Bayhill Therapeutics says it has begun dosing patients with BHT-3009, its experimental drug candidate, in a Phase II
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 April 2006
10 April 2006
23 May 2013
© 2013 thepharmaletter.com